Our Team

BRIM Biotechnology brings together experts across science, engineering, and technology disciplines to deliver a more efficient, less costly, drug development process. Our talented team has forged decades worth of strong global connections and experience. We operate based on a virtual team model, integrating our expert R&D operation team in Taiwan with our skilled overseas scientific team. We have years of experience working in technological and pharmaceutical development, regulatory affairs, and marketing and IP, with expertise across the field of innovative drug development, including pre-clinical toxicology, clinical pharmacology, and management. We harness the power of our team’s expertise in translational science to deliver a difference for patients.

Translational Science Expertise

BRIM R&D Operational Team

BRIM R&D

Operational Team

BRIM R&D

Operational Team

Pre-clinical & Toxicology

Dr. Frank Lee

Chief Scientific Officer

Dr. Frank Lee

Chief Scientific Officer

Dr. Carl Alden

Senior Consultant

Dr. Carl Alden

Senior Consultant

Previously Vice President at Millennium

Held various roles at Searle, Monsanto, Pharmacia & P&G

Served as Editor of Veterinary Pathology and Toxicology Pathology and President at Society of Toxicology Pathologist

Clinical Pharmacology & Clinical Management

Wen Chyi Shyu, PhD

CEO

Wen Chyi Shyu, PhD

CEO

Vice President of Global Drug Metabolism and Pharmacokinetics at Takeda

30+ years of experience in drug metabolism and pharmacokinetics

Haishan Jang, PhD, MBA

Vice Chairman, CGS (Chief Global Strategist)

Haishan Jang, PhD, MBA

Vice Chairman, CGS (Chief Global Strategist)

Dr. Conrad Tou

Senior Consultant

Dr. Conrad Tou

Senior Consultant

30+ years of experience in biotech and large pharmaormer director at Hollis-Eden pharma

Held several positions at Sanofi-Winthrop and AstraZeneca, with expertise in statistics and data management

CMC & Pharmaceutical Development

Dr. Wayne Liaw

Senior Consultant

Dr. Wayne Liaw

Senior Consultant

Previously held Senior Director positions at Otonomy and Optimer

Former director at Hollis-Eden pharma

Regulation

Dr. Li-Chun C. Wang”

Senior Consultant

Dr. Li-Chun C. Wang

Senior Consultant

President, LCWANG Regulatory Consulting, LLC

Previously held Vice President of Regulatory CMC at Solid Biosciences

40+ years of experience in drug development

Marketing and IP

Dr. Chyau Liang

Senior Consultant

Dr. Chyau Liang

Senior Consultant

Previously Partner at Osha Liang LLP

Former Professor at the University of Texas-Houston School of Medicine

SABs & KOLs

Dr. Pan-Chyr Yang

Scientific Board Member

Dr. Pan-Chyr Yang

Scientific Board Member

Academician at Academia Sinica and Professor at National Taiwan University

Previously President of National Taiwan University

Editor-in-Chief of MicroRNA and Lung Cancer: Targets and Therapy

Dr. Robert Ruffolo

Scientific Board Member

Dr. Robert Ruffolo

Scientific Board Member

Previously President of R&D and Corporate Senior Vice President of Wyeth Pharmaceuticals

Senior Vice President and Director of Research at SmithKline Beecham Pharmaceuticals

Chairman of the Cardiovascular Research Committee at Eli Lilly & Company

Dr. Eliot Lazar

Key Opinion Leader

Dr. Eliot Lazar

Key Opinion Leader

CEO at elCON Medical Consulting

Previously held Assistant Professor positions at the State University of NY and the University of Rochester

Leadership Team

Wen Chyi Shyu, PhD CEO With more than three decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.Wen Chyi brings to BRIM extensive industry experience and a passion for driving innovation in the drug discovery and development process. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.Wen Chyi has a passion for developing people. Through training and motivation, research scientists can be developed into successful pharmaceutical executives to build international and multi-disciplinary teams. She, as an example, has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.

Wen Chyi Shyu, PhD

CEO

With more than three decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.Wen Chyi brings to BRIM extensive industry experience and a passion for driving innovation in the drug discovery and development process. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.Wen Chyi has a passion for developing people. Through training and motivation, research scientists can be developed into successful pharmaceutical executives to build international and multi-disciplinary teams. She, as an example, has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.

Mei-Hui Kuo, MS Chief Operation Officer Ms. Mei-Hui Kuo has over 35 years of experience in the biotechnology pharmaceutical industry. She was the founding COO of BRIM and now has returned to work with the new management team to reach BRIM′s operation goals. In her career, she has served successfully in many key positions including COO at Senhwa Biosciences, VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.

Mei-Hui Kuo, MS

Chief Operation Officer

Ms. Mei-Hui Kuo has over 35 years of experience in the biotechnology pharmaceutical industry. She was the founding COO of BRIM and now has returned to work with the new management team to reach BRIM′s operation goals. In her career, she has served successfully in many key positions including COO at Senhwa Biosciences, VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.

Frank W. Lee, PhD CSO Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn^®, Anaprox^®, and Ticlid^®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs. Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.

Frank W. Lee, PhD

CSO

Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn^®, Anaprox^®, and Ticlid^®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs. Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.

Haishan Jang, PhD, MBA Vice Chairman, CGS (Chief Global Strategist) Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.

Haishan Jang, PhD, MBA

Vice Chairman, CGS (Chief Global Strategist)

Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.

Erin Chang, MS SVP of Portfolio Development Erin Chang gained her Master of Science degree from the Graduate Institute of Toxicology at the National Taiwan University. She has more than 15 years of experience in new drug development and project management and worked at TTY Biopharm and Taiwan Liposome Company. Erin is also experienced in the incubation of academic projects, portfolio and risk management, patent portfolio management, and process management. Erin has participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.

Erin Chang, MS

SVP of Portfolio Development

Erin Chang gained her Master of Science degree from the Graduate Institute of Toxicology at the National Taiwan University. She has more than 15 years of experience in new drug development and project management and worked at TTY Biopharm and Taiwan Liposome Company. Erin is also experienced in the incubation of academic projects, portfolio and risk management, patent portfolio management, and process management. Erin has participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.

Yi-Chun Maria Chen, PhD VP of Business Development Dr. Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. Maria received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.

Yi-Chun Maria Chen, PhD

VP of Business Development

Dr. Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. Maria received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.

Amanda Yen VP of Finance Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.

Amanda Yen

VP of Finance

Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.

Scientific Consultants

Carl Alden, DVM, DACVP Senior Toxicology Consultant

Dr. Alden is a veterinarian by training with more than 40 years of pharmaceutical industry toxicology/pathology experience at companies such as Millennium, Searle, Monsanto, Pharmacia, and Procter & Gamble. He retired as the VP of Toxicology at Millennium Pharmaceuticals (Takeda).

Carl Alden, DVM, DACVP

Senior Toxicology Consultant

Dr. Alden is a veterinarian by training with more than 40 years of pharmaceutical industry toxicology/pathology experience at companies such as Millennium, Searle, Monsanto, Pharmacia, and Procter & Gamble. He retired as the VP of Toxicology at Millennium Pharmaceuticals (Takeda).

Conrad Tou, PhD Senior Statistics Consultant

Dr. Tou has over 30 years of work experience in biotech and major pharmaceutical companies, such as Sanofi-Synthelabo, Sterling-Winthrop, P&G, and AstraZeneca. He was formerly the associate director of Statistics at AstraZeneca and has extensive expertise in statistics and data management.

Conrad Tou, PhD

Senior Statistics Consultant

Dr. Tou has over 30 years of work experience in biotech and major pharmaceutical companies, such as Sanofi-Synthelabo, Sterling-Winthrop, P&G, and AstraZeneca. He was formerly the associate director of Statistics at AstraZeneca and has extensive expertise in statistics and data management.

Chyau Liang, PhD, JD Senior IP Law Consultant

Dr. Liang has more than 30 years of experience. He has established his own patent law firm and has qualifications as a US lawyer, a patent attorney, and a Taiwan patent attorney. Prior to that, he was a senior partner at Osha Liang LLP and a professor at the University of Texas-Houston School of Medicine. He is experienced in international patents, strategy analysis, patent application & litigation, IP management, and consulting.

Chyau Liang, PhD, JD

Senior IP Law Consultant

Dr. Liang has more than 30 years of experience. He has established his own patent law firm and has qualifications as a US lawyer, a patent attorney, and a Taiwan patent attorney. Prior to that, he was a senior partner at Osha Liang LLP and a professor at the University of Texas-Houston School of Medicine. He is experienced in international patents, strategy analysis, patent application & litigation, IP management, and consulting.

Wayne Liaw, PhD Senior Formulation & CMC Consultant

Dr. Liaw has more than 30 years of experience in formulation and CMC. He has extensive experience in developing drug formulations in small molecules, big molecules, and peptides, as well as in drug delivery development and dosing pathway design. Dr. Liaw was responsible for senior management in U.S. companies such as Syntex and Optimer Biotech.

Wayne Liaw, PhD

Senior Formulation & CMC Consultant

Dr. Liaw has more than 30 years of experience in formulation and CMC. He has extensive experience in developing drug formulations in small molecules, big molecules, and peptides, as well as in drug delivery development and dosing pathway design. Dr. Liaw was responsible for senior management in U.S. companies such as Syntex and Optimer Biotech.

Dr. Li-Chun C. Wang Senior Consultant President, LCWANG Regulatory Consulting, LLC Previously held Vice President of Regulatory CMC at Solid Biosciences 40+ years of experience in drug development

Dr. Li-Chun C. Wang

Senior Consultant

President, LCWANG Regulatory Consulting, LLC Previously held Vice President of Regulatory CMC at Solid Biosciences 40+ years of experience in drug development